Prevail Therapeutics, Inc. develops therapeutics for neurodegenerative diseases. The firm engages in the research and development of novel biologic gene therapies to treat Parkinson's disease and other neurodegenerative diseases. The company was founded by Asa Abeliovich on July 6, 2017 and is headquartered in New York, NY.
Company profile
Ticker
PRVL
Exchange
Website
CEO
Asa Abeliovich
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
PRVL stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
1 Feb 21
EFFECT
Notice of effectiveness
27 Jan 21
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Jan 21
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Jan 21
POS AM
Prospectus update (post-effective amendment)
22 Jan 21
8-K
Completion of Acquisition or Disposition of Assets
22 Jan 21
SC 14D9/A
Tender offer solicitation (amended)
22 Jan 21
25-NSE
Exchange delisting
22 Jan 21
SC TO-T/A
Third party tender offer statement (amended)
22 Jan 21
SC 14D9/A
Tender offer solicitation (amended)
20 Jan 21
Transcripts
Latest ownership filings
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
16 Feb 21
SC 13G/A
CITADEL ADVISORS LLC
16 Feb 21
SC 13G/A
EcoR1 Capital, LLC
12 Feb 21
SC 13G/A
REGENXBIO Inc.
12 Feb 21
SC 13G
JNE Partners LLP
29 Jan 21
SC 13D/A
ORBIMED ADVISORS LLC
29 Jan 21
4
Change in insider ownership
26 Jan 21
4
Asa Abeliovich
26 Jan 21
4
Timothy M Adams
26 Jan 21
4
William H. Carson
26 Jan 21
Financial summary
Quarter (USD) | Sep 20 | Jun 20 | Mar 20 | Sep 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 19 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 81.82 mm | 81.82 mm | 81.82 mm | 81.82 mm | 81.82 mm | 81.82 mm |
Cash burn (monthly) | 9.78 mm | 10.03 mm | 6.21 mm | 6.78 mm | 6.20 mm | 6.60 mm |
Cash used (since last report) | 419.87 mm | 430.72 mm | 266.58 mm | 291.08 mm | 266.12 mm | 283.54 mm |
Cash remaining | -338.05 mm | -348.89 mm | -184.76 mm | -209.26 mm | -184.30 mm | -201.72 mm |
Runway (months of cash) | -34.6 | -34.8 | -29.8 | -30.9 | -29.7 | -30.6 |
Institutional ownership, Q1 2023
55.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 235.73 mm |
Total shares | 18.86 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
LLY Lilly(Eli) & Co | 18.86 mm | $235.73 mm |